Zomedica Pharmaceuticals Corp (ZOM) - Net Assets
Based on the latest financial reports, Zomedica Pharmaceuticals Corp (ZOM) has net assets worth $132.44 Million USD as of March 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($142.99 Million) and total liabilities ($10.55 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Zomedica Pharmaceuticals Corp liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $132.44 Million |
| % of Total Assets | 92.62% |
| Annual Growth Rate | 88.64% |
| 5-Year Change | 283.16% |
| 10-Year Change | 5168.22% |
| Growth Volatility | 899.14 |
Zomedica Pharmaceuticals Corp - Net Assets Trend (2012–2024)
This chart illustrates how Zomedica Pharmaceuticals Corp's net assets have evolved over time, based on quarterly financial data. Also explore Zomedica Pharmaceuticals Corp balance sheet assets for the complete picture of this company's asset base.
Annual Net Assets for Zomedica Pharmaceuticals Corp (2012–2024)
The table below shows the annual net assets of Zomedica Pharmaceuticals Corp from 2012 to 2024. For live valuation and market cap data, see ZOM company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $195.66 Million | -18.48% |
| 2023-12-31 | $240.02 Million | -10.24% |
| 2022-12-31 | $267.39 Million | -1.29% |
| 2021-12-31 | $270.89 Million | +430.46% |
| 2020-12-31 | $51.07 Million | +2336.98% |
| 2019-12-31 | $2.10 Million | -42.70% |
| 2018-12-31 | $3.66 Million | -16.64% |
| 2017-12-31 | $4.39 Million | +6.11% |
| 2016-12-31 | $4.13 Million | +11.32% |
| 2015-12-31 | $3.71 Million | +2526.45% |
| 2014-12-31 | $141.41K | -31.48% |
| 2013-12-31 | $206.38K | +114.23% |
| 2012-12-31 | $96.34K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Zomedica Pharmaceuticals Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 21791365592.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $380.97 Million | 194.71% |
| Other Comprehensive Income | $88.00K | 0.04% |
| Other Components | $32.52 Million | 16.62% |
| Total Equity | $195.66 Million | 100.00% |
Zomedica Pharmaceuticals Corp Competitors by Market Cap
The table below lists competitors of Zomedica Pharmaceuticals Corp ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
INTER RAO Lietuva AB
WAR:IRL
|
$53.94 Million |
|
Pansari Developers Limited
NSE:PANSARI
|
$53.94 Million |
|
SK Innovation Co Ltd Pref
KO:096775
|
$53.98 Million |
|
Defiance Silver Corp
V:DEF
|
$53.98 Million |
|
A-Tech Solution Co. Ltd
KQ:071670
|
$53.88 Million |
|
R K Swamy Limited
NSE:RKSWAMY
|
$53.87 Million |
|
Prestige Wealth Inc.
NASDAQ:AURE
|
$53.87 Million |
|
Hotelim Société Anonyme
PA:MLHOT
|
$53.86 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Zomedica Pharmaceuticals Corp's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 240,017,000 to 195,664,000, a change of -44,353,000 (-18.5%).
- Net loss of 46,982,000 reduced equity.
- Other comprehensive income increased equity by 40,000.
- Other factors increased equity by 2,589,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-46.98 Million | -24.01% |
| Other Comprehensive Income | $40.00K | +0.02% |
| Other Changes | $2.59 Million | +1.32% |
| Total Change | $- | -18.48% |
Book Value vs Market Value Analysis
This analysis compares Zomedica Pharmaceuticals Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.28x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.09x to 0.28x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | $0.61 | $0.06 | x |
| 2014-12-31 | $0.14 | $0.06 | x |
| 2015-12-31 | $0.08 | $0.06 | x |
| 2016-12-31 | $0.05 | $0.06 | x |
| 2017-12-31 | $0.05 | $0.06 | x |
| 2018-12-31 | $0.04 | $0.06 | x |
| 2019-12-31 | $0.02 | $0.06 | x |
| 2020-12-31 | $0.14 | $0.06 | x |
| 2021-12-31 | $0.28 | $0.06 | x |
| 2022-12-31 | $0.27 | $0.06 | x |
| 2023-12-31 | $0.24 | $0.06 | x |
| 2024-12-31 | $0.20 | $0.06 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Zomedica Pharmaceuticals Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -24.01%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -172.19%
- • Asset Turnover: 0.13x
- • Equity Multiplier: 1.06x
- Recent ROE (-24.01%) is above the historical average (-157.01%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | -37.55% | 0.00% | 0.00x | 1.02x | $-98.13K |
| 2014 | -29.99% | 0.00% | 0.00x | 1.03x | $-56.55K |
| 2015 | -1.47% | 0.00% | 0.00x | 1.04x | $-425.92K |
| 2016 | -145.43% | 0.00% | 0.00x | 1.18x | $-6.43 Million |
| 2017 | -183.84% | 0.00% | 0.00x | 1.19x | $-8.50 Million |
| 2018 | -455.23% | 0.00% | 0.00x | 1.65x | $-17.01 Million |
| 2019 | -945.96% | 0.00% | 0.00x | 2.00x | $-20.03 Million |
| 2020 | -33.14% | -119804.00% | 0.00x | 1.30x | $-22.03 Million |
| 2021 | -6.79% | -444.78% | 0.01x | 1.04x | $-45.47 Million |
| 2022 | -6.36% | -89.88% | 0.07x | 1.05x | $-43.75 Million |
| 2023 | -14.39% | -137.10% | 0.10x | 1.05x | $-58.53 Million |
| 2024 | -24.01% | -172.19% | 0.13x | 1.06x | $-66.55 Million |
Industry Comparison
This section compares Zomedica Pharmaceuticals Corp's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $934,445,541
- Average return on equity (ROE) among peers: -53.57%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Zomedica Pharmaceuticals Corp (ZOM) | $132.44 Million | -37.55% | 0.08x | $53.90 Million |
| Abbott Laboratories (ABT) | $9.06 Billion | 17.11% | 1.57x | $151.99 Billion |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $12.40 Million | -202.26% | 2.49x | $18.68 Million |
| Aethlon Medical Inc (AEMD) | $-3.07 Million | 0.00% | 0.00x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $-11.59 Million | 0.00% | 0.00x | $903.35K |
| Adapthealth Corp (AHCO) | $245.55 Million | 0.85% | 0.03x | $1.39 Billion |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $4.29 Million | -149.07% | 0.49x | $10.14 Million |
| Allurion Technologies, Inc. (ALUR) | $-77.98 Million | 0.00% | 0.00x | $10.18 Million |
| Autonomix Medical, Inc. Common Stock (AMIX) | $8.10 Million | -140.88% | 0.21x | $3.99 Million |
| Artivion Inc (AORT) | $80.40 Million | 8.08% | 0.22x | $1.09 Billion |
| Apyx Medical Inc (APYX) | $26.92 Million | -69.51% | 1.94x | $153.68 Million |
About Zomedica Pharmaceuticals Corp
Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company offers diagnostic products comprising TRUFORMA Bulk Acoustic Wave point of care diagnostic platform; TRUVIEW, a digital cystoscopy platform that offers automated slide preparation within the instrument; and VetGuardian, a zero-touch vital sign… Read more